Notably, systemic IL4R-Exo(si/mi) administration hindered tumor growth, lowered M2 cytokines and immune-suppressive cell levels, and elevated M1 cytokines and immune-stimulatory cell levels, significantly outperforming control exosomes. This evidence concerns the gene IL4R and neoplasm.